Late-Breaking Science at the Annual Meeting
The Late-Breaking Science Program highlights the most current research by neurologists, neuroscientists, and other applicable researchers whose work is of major scientific importance or interest and warrants expedited presentation and publication.
Key aspects of the research must have been conducted after November 1, 2007.
2008 Late-Breaking Science Abstracts
Abstracts qualify for Late-Breaking Science presentation if they present key aspects of research conducted after the November 1, 2007, abstract submission deadline; additionally, they must be new and of sufficient scientific important to warrant expedited presentation and publication. A list of the accepted abstract titles is below. View a complete list of abstracts.
LBS: Late-Breaking Science—Wednesday, April 16, 2008
Room 196ABC 5:30 p.m.–6:45 p.m.
LBS.001 "Outbreak of Immune Polyradiculoneuropathy in Workers Exposed to Porcine Neural Tissue" Daniel H. Lachance, Rochester, MN
LBS.002 "Acute Severe Model of Anti-Muscle Specific Kinase (MuSK) Myasthenia in Lewis Rats" David P. Richman, Davis, CA
LBS.003 "Treatment with glatiramer acetate delays conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS)" Giancarlo Comi, Milan, Italy
LBS.004 "Interferon beta-1b 500mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) study" Paul O'Connor, Toronto, Ontario, Canada
LBS.005 "The LEADe Study: A Randomized, Controlled Trial Investigating the Effect of Atorvastatin on Cognitive and Global Function in Patients With Mild-to-Moderate Alzheimer's Disease Receiving Background Therapy of Donepezil" Howard Feldman, Vancouver, British Columbia, Canada
LB1: Late-Breaking Science—Tuesday, April 15, 2008
Exhibition Hall, Poster Session I, 7:00 a.m.–10:00 a.m. (Senior Authors stand-by time 7:00 a.m.–8:30 a.m.
LB1.001 "Autophagy independent suppression of CGG Repeat-Induced Neurodegeneration by HDAC 6 in a Drosophila Model of Fragile X Tremor Ataxia Syndrome" Peter K. Todd, Philadelphia, PA
LB1.002 "Improved symptom control with fixed dose levodopa/carbidopa/entacapone versus levodopa/carbidopa as first-line levodopa therapy in early Parkinson?s disease (PD) patients" Robert A. Hauser, Tampa, FL
LB1.003 "Abnormal Metabolic Brain Network in Parkinsonian Macaques: Modulation by Retinal Pigment Epithelial (RPE) Cell (Spheramine®) Implantation" Yilong Ma, Manhasset, NY
LB1.004 "Efficacy of Donepezil in CADASIL: A model of Subcortical Vascular Cognitive Impairment" Stephen Salloway, Providence, RI
LB2: Late Breaking Science—Tuesday, April 15, 2008
Exhibition Hall, Poster Session II, 11:30 a.m.–2:30 p.m. (Senior Author stand-by time 12:00 p.m.–1:30 p.m.)
LB2.001 "Results from a Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety and Efficacy of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), for the Treatment of Pompe Disease in Juveniles and Adults" A.T. van der Ploeg, Rotterdam, The Netherlands
LB2.002 "Oral Dexamethasone Pulse Therapy Versus Daily Prednisole in Subacute Inflammatory Myopathies: A Randomized Clinical Trial" Janneke van de Vlekkert, Amsterdam, Netherlands
LB2.003 "Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance" Fanny Mochel, Dallas, TX